a public good project by the
Synthesis
Company
of California

© 2026

Akihiko Kawahara | doi.page

0 works0 citations0 h-index

Akihiko Kawahara

Toho University(JP)Kurume University Hospital(JP)Toho University Medical Center Sakura Hospital(JP)

Publications by Year

Research Areas

Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Immunotherapy and Immune Responses, Pancreatic and Hepatic Oncology Research, Salivary Gland Tumors Diagnosis and Treatment

Most-Cited Works

→ Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer(2014)673 cited
→ Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer(2015)428 cited
→ Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy(2016)187 cited
→ Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer(2014)175 cited
→ Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin β1/Src/Akt-Driven Bypass Signaling(2013)165 cited
→ Tumor Growth Suppression in Pancreatic Cancer by a Putative Metastasis Suppressor Gene Cap43/NDRG1/Drg-1 through Modulation of Angiogenesis

(2006)

159 cited

→ Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations(2010)152 cited

→ FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis(2013)148 cited

→ Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis(2010)114 cited

→ FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor(2014)108 cited